KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $795.0 million.

  • Boston Scientific's Other Accumulated Expenses fell 1037.2% to $795.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $795.0 million, marking a year-over-year decrease of 1037.2%. This contributed to the annual value of $795.0 million for FY2025, which is 1037.2% down from last year.
  • As of Q4 2025, Boston Scientific's Other Accumulated Expenses stood at $795.0 million, which was down 1037.2% from $862.0 million recorded in Q3 2025.
  • Boston Scientific's Other Accumulated Expenses' 5-year high stood at $1.0 billion during Q1 2022, with a 5-year trough of $669.0 million in Q3 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $804.5 million (2023), whereas its average is $824.9 million.
  • Per our database at Business Quant, Boston Scientific's Other Accumulated Expenses soared by 4666.67% in 2022 and then tumbled by 2388.78% in 2023.
  • Quarter analysis of 5 years shows Boston Scientific's Other Accumulated Expenses stood at $783.0 million in 2021, then decreased by 2.81% to $761.0 million in 2022, then rose by 6.96% to $814.0 million in 2023, then grew by 8.97% to $887.0 million in 2024, then fell by 10.37% to $795.0 million in 2025.
  • Its Other Accumulated Expenses stands at $795.0 million for Q4 2025, versus $862.0 million for Q3 2025 and $952.0 million for Q2 2025.